Lineage Cell Therapeutics, Inc. (LCTX) Net Income by Year
Lineage Cell Therapeutics, Inc. reported a net loss of $63.5M in fiscal year 2025. This represents a decrease of 241.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $32.3M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Lineage Cell Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LCTX Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$32.3M | -$63.5M-241.4% | -$18.6M+13.4% | -$21.5M+18.2% | -$26.3M+38.9% | -$43.0M-108.3% | -$20.6M-76.4% | -$11.7M+74.5% | -$46.0M-130.2% | -$20.0M-159.5% | $33.6M+171.4% | -$47.0M-29.1% | -$36.4M+17.0% | -$43.9M-104.8% | -$21.4M-29.7% | -$16.5M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
LCTX Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Lineage Cell Therapeutics, Inc. financials
Frequently Asked Questions
What was Lineage Cell Therapeutics, Inc.'s net income in fiscal year 2025?
Lineage Cell Therapeutics, Inc. reported a net loss of $63.5M in fiscal year 2025.
How fast is Lineage Cell Therapeutics, Inc.'s net income growing?
Lineage Cell Therapeutics, Inc. (LCTX) net income fell by 241.4% year over year, from -$18.6M to -$63.5M in fiscal year 2025.
What is Lineage Cell Therapeutics, Inc.'s net income over the last twelve months?
Lineage Cell Therapeutics, Inc. (LCTX) reported a $32.3M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Lineage Cell Therapeutics, Inc.'s net income changed over the years?
Across the 15 fiscal years this page covers, Lineage Cell Therapeutics, Inc. (LCTX) net income went from -$16.5M in fiscal year 2011 to -$63.5M in fiscal year 2025.
What was Lineage Cell Therapeutics, Inc.'s net income in the most recent quarter?
Lineage Cell Therapeutics, Inc. (LCTX) reported $1.5M in net income in Q2 2026. This represents an increase of 104.9% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Lineage Cell Therapeutics, Inc. (LCTX) reported on that line in every period on record.